Abstract: The present invention provides a compound of Formula (I) being capable of modulating the activity of histone lysine demethylase (KDM), pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The compound of Formula (I) acts as KDM inhibitor with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to KDM dysregulation.
Type:
Grant
Filed:
October 27, 2015
Date of Patent:
December 5, 2017
Assignee:
DONG-A ST CO., LTD.
Inventors:
Myeong-seop Kim, Taesun Park, Taeyoung Yoon, Seung Min Yang, Hae-Sun Kim, Jun Gyu Kim
Abstract: Provided is a composition of a ready-to-use injectable solution comprising pemetrexed or pharmaceutically acceptable salts thereof, containing pemetrexed; anhydrous sodium sulfite; and N-acetyl-L-cystein. With respect to use as an injectable preparation. The ready-to-use injectable solution composition is suitable for effective administration of pemetrexed since a melting process of main ingredients is not necessary before administration, and the composition can be used by being diluted immediately in a perfusate. In addition, the properties of the composition do not change even in long-term storage, and pharmaceutical stability is significantly improved by inhibiting related substances below a reference, whereby the composition can be stored in a liquid preparation state.
Type:
Application
Filed:
November 6, 2015
Publication date:
November 30, 2017
Applicant:
DONG-A ST CO., LTD
Inventors:
Mi-Won SOHN, Sun-Woo JANG, Dong-Han WON, Yong-Min KIM, Hyung-Don HWANG, Dong-Hun MIN
Abstract: Provided are biphenyl derivatives having the structure of Formula 1: stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen, halogen, hydroxy, substituted or unsubstituted C1-C6 alkyl, or C1-C6 alkoxy; R2, R3 and R4 are each independently hydrogen, halogen, substituted or unsubstituted amino, nitro, cyano, hydroxy, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, or —C(O)R6; R5 is hydrogen or C1-C6 alkyl; n is 0 or 1; and R6 is hydrogen or amino, methods for preparing the same, and a pharmaceutical composition containing the same.
Type:
Grant
Filed:
July 17, 2014
Date of Patent:
November 28, 2017
Assignee:
DONG-A ST CO., LTD
Inventors:
Soon-Hoe Kim, Weon-Bin Im, Chong-Hwan Cho, Sun-Ho Choi, Jung-Sang Park, Mi-Yeon Kim, Sung-Hak Choi, Min-Jung Lee, Kang-Hun Cho
Abstract: A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer.
Type:
Grant
Filed:
May 30, 2014
Date of Patent:
November 21, 2017
Assignees:
DONG-A SOCIO HOLDINGS CO., LTD., DONG-A ST CO., LTD
Inventors:
Hyounmie Doh, Byong Moon Kim, Chae Young Kim, Sung-Hee Lee, Dong-Hyeon Kim, Yoo-jin Kim, Dongsop Lee, Kyung Mi Han, Dongsup Song, Eun-ee Jung, Jinseok Lee, Woo Jin Seung, Kyusang Hwang
Abstract: Provided are novel selective androgen receptor agonists, a preparation method thereof, and a pharmaceutical composition including the same at a pharmaceutically effective amount. The selective androgen receptor agonists according to the present invention act on androgen receptors to increase androgen activity, thereby being usefully applied as a therapeutic and prophylactic agent for diseases or conditions, of which symptoms may be improved or may respond to treatment by increased activities of androgen receptors, namely, a variety of hormone-related diseases in male and female, muscle wasting disorders, osteoporosis, etc.
Type:
Grant
Filed:
April 7, 2015
Date of Patent:
November 7, 2017
Assignee:
DONG-A ST CO., LTD.
Inventors:
Sung Pil Choi, Seul Min Choi, Byoung Hwa Son, Hyun Jung Kim, Ju Mi Kim, Byung Jun Jang, Ji Hyun Sung, Ji Hye Lee, Eunjin Kim, Kyung Koo Kang, Soon-Hoe Kim
Abstract: The present invention relates to a method for preparing N-[[1-{3-(1,2,3-triazol-1-yl)propyl}piperidin-4-yl]methyl]-4-amino-5-chloro-2-methoxybenzamide, which is a novel benzamide derivative as a 5-HT4 receptor agonist, or a pharmaceutically acceptable salt thereof; to a novel intermediate capable of being used in the preparation of the compounds; and to a method for preparing the same. The preparation methods of the present invention can be useful for mass production since a low-priced reagent and intermediate are used and the number of reaction processes is decreased, thereby saving preparation costs and improving the yield.
Type:
Grant
Filed:
July 11, 2014
Date of Patent:
September 26, 2017
Assignee:
DONG-A ST CO., LTD
Inventors:
Woo Young Kwak, Kyung Seok Lee, Ullapu Punna Reddy, Soon Kyu Jung, Tae Sun Park, Joong In Lim
Abstract: The present invention relates to a pharmaceutical composition for treating and preventing degenerative neurological disorders, containing, as an active ingredient, a mixture extract of two or more types selected from the group consisting of Moutan Root Bark, Angelica Dahurica Root, and Bupleurum Root, or a fraction thereof.
Type:
Application
Filed:
March 8, 2017
Publication date:
August 10, 2017
Applicants:
UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY, DONG-A ST CO., LTD.
Inventors:
Youngmi KIM, Myung Sook OH, Seon-Pyo HONG, Mi Won SOHN, Jin Seok JEONG, Hai Hua JIANG, Eunjin KIM, Ja Young RYU, Young Woong CHO, Xiao Fei DU, Sang Zin CHOI, Jeong Soo KIM, Byoung Moon KIM
Abstract: The present invention relates to a novel tricyclic benzoxaborole derivative, a preparation method thereof, and use of antibiotics pharmaceutical composition including the same as an active ingredient.
Type:
Grant
Filed:
July 28, 2014
Date of Patent:
June 13, 2017
Assignee:
DONG-A ST CO., LTD.
Inventors:
Soon-Hoe Kim, Weon-Bin Im, Seung-Bum Ha, Jung-Sang Park, Mi-Yeon Kim, Sung-Hak Choi, Hyun-Jung Sung
Abstract: Provided are novel selective androgen receptor agonists, a preparation method thereof, and a pharmaceutical composition including the same at a pharmaceutically effective amount. The selective androgen receptor agonists according to the present invention act on androgen receptors to increase androgen activity, thereby being usefully applied as a therapeutic and prophylactic agent for diseases or conditions, of which symptoms may be improved or may respond to treatment by increased activities of androgen receptors, namely, a variety of hormone-related diseases in male and female, muscle wasting disorders, osteoporosis, etc.
Type:
Application
Filed:
April 7, 2015
Publication date:
February 23, 2017
Applicant:
DONG-A ST CO., LTD.
Inventors:
Sung Pil Choi, Seul Min Choi, Byoung Hwa Son, Hyun Jung Kim, Ju Mi Kim, Byung Jun Jang, Ji Hyun Sung, Ji Hye Lee, Eunjin Kim, Kyung Koo Kang, Soon-Hoe Kim
Abstract: Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against CETP, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against CETP, the oxazolidinone derivative can be effectively applied to the prevention or treatment of various CETP enzyme activity- or HDL cholesterol level-related diseases such as dyslipidemia, atherosclerosis, and coronary heart disease.
Type:
Grant
Filed:
March 28, 2014
Date of Patent:
January 3, 2017
Assignee:
DONG-A ST CO., LTD.
Inventors:
Jang Hyun Park, Seung Hyun Song, Han Kook Chung, Heung Jae Kim, Ji Hye Lee, Byung Jun Jang, Eun Jung Kim, Hae Hum Jung, Chae Lim Ryu, Jae-Sung Hwang, Hyung Ki Lee, Kyung Koo Kang, Soon-Hoe Kim
Abstract: The present invention relates to a method for preparing N-[[1-{3-(1,2,3-triazol-1-yl)propyl}piperidin-4-yl]methyl]-4-amino-5-chloro-2-methoxybenzamide, which is a novel benzamide derivative as a 5-HT4 receptor agonist, or a pharmaceutically acceptable salt thereof; to a novel intermediate capable of being used in the preparation of the compounds; and to a method for preparing the same. The preparation methods of the present invention can be useful for mass production since a low-priced reagent and intermediate are used and the number of reaction processes is decreased, thereby saving preparation costs and improving the yield.
Type:
Application
Filed:
July 11, 2014
Publication date:
June 30, 2016
Applicant:
DONG-A ST CO., LTD
Inventors:
Woo Young KWAK, Kyung Seok LEE, Ullapu Punna REDDY, Soon Kyu Jung, Tae Sun PARK, Joong In LIM
Abstract: The present invention relates to a novel liquid composition comprised of piroxicam or its pharmaceutically acceptable salt (a non-steroid anti-inflammatory drug) and hyaluronic acid or its pharmaceutically acceptable salt (used for treatment of degenerative arthritis). Specifically, the invention provides a highly physicochemically stable liquid injection, comprising piroxicam and hyaluronic acid as active ingredients and ?-cyclodextrin or its derivative and polyethylene glycol as additives to enhance its physicochemical stability, and the preparation method thereof.
Type:
Grant
Filed:
March 7, 2013
Date of Patent:
June 28, 2016
Assignee:
DONG-A ST CO., LTD.
Inventors:
Soon-Hoe Kim, Mi-Won Son, Sun-Woo Jang, Myung-Joo Kang, Kyung-Wan Ma
Abstract: The present invention relates to a novel tricyclic benzoxaborole derivative, a preparation method thereof, and use of antibiotics pharmaceutical composition including the same as an active ingredient.
Type:
Application
Filed:
July 28, 2014
Publication date:
June 16, 2016
Applicant:
DONG-A ST CO., LTD.
Inventors:
Soon-Hoe Kim, Weon-Bin Im, Seung-Bum Ha, Jung-Sang Park, Mi-Yeon Kim, Sung-Hak Choi, Hyun-Jung Sung
Abstract: A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer.
Type:
Application
Filed:
May 30, 2014
Publication date:
May 5, 2016
Applicants:
DONG-A SOCIO HOLDINGS CO., LTD., DONG-A ST CO., LTD
Inventors:
Hyounmie DOH, Byong Moon KIM, Chae Young KIM, Sung-Hee LEE, Dong-Hyeon KIM, Yoo-jin KIM, Dongsop LEE, Kyung Mi HAN, Dongsup SONG, Eun-ee JUNG, Jinseok LEE, Woo Jin SEUNG, Kyusang HWANG
Abstract: A pharmaceutical composition for the treatment of osteoarthritis comprising piroxicam or pharmaceutically acceptable salt thereof and hyaluronic acid or pharmaceutically acceptable salt thereof at a specific ratio is provided. The composition generates synergistic effect on both anti-inflammatory and analgesic effects simultaneously. The pharmaceutical composition contains 0.25-10.0 wt % of piroxicam or its pharmaceutically acceptable salt and 0.5-5.0 wt % of hyaluronic acid or its pharmaceutically acceptable salt, wherein the weight ratio between piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt is between 1:1 and 1:3.
Type:
Application
Filed:
May 27, 2014
Publication date:
April 21, 2016
Applicant:
DONG-A ST CO., LTD.
Inventors:
Soon-Hoe KIM, Mi-Won SON, Sun-Woo JANG, Chan-Woong PARK, Kyung-Wan MA, Sang-Won JUNG
Abstract: Disclosed are a novel oxazolidinone derivative exhibiting inhibitory activity against CETP, a preparation method thereof, and a pharmaceutical composition comprising the same. Exhibiting excellent inhibitory activity against CETP, the oxazolidinone derivative can be effectively applied to the prevention or treatment of various CETP enzyme activity- or HDL cholesterol level-related diseases such as dyslipidemia, atherosclerosis, and coronary heart disease.
Type:
Application
Filed:
March 28, 2014
Publication date:
February 11, 2016
Applicant:
DONG-A ST CO., LTD.
Inventors:
Jang Hyun Park, Seung Hyun Song, Han Kook Chung, Heung Jae Kim, Ji Hye Lee, Byung Jun Jang, Eun Jung Kim, Hae Hum Jung, Chae Lim Ryu, Jae-Sung Hwang, Hyung Ki Lee, Kyung Koo Kang, Soon-Hoe Kim
Abstract: The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.
Type:
Grant
Filed:
April 15, 2013
Date of Patent:
October 20, 2015
Assignee:
DONG-A ST CO., LTD.
Inventors:
Jae Keol Rhee, Weon Bin Im, Chong Hwan Cho, Sung Hak Choi, Tae Ho Lee
Abstract: The present invention relates to a novel liquid composition comprised of piroxicam or its pharmaceutically acceptable salt (a non-steroid anti-inflammatory drug) and hyaluronic acid or its pharmaceutically acceptable salt (used for treatment of degenerative arthritis). Specifically, the invention provides a highly physicochemically stable liquid injection, comprising piroxicam and hyaluronic acid as active ingredients and ?-cyclodextrin or its derivative and polyethylene glycol as additives to enhance its physicochemical stability, and the preparation method thereof. Therefore, the novel composition and the formulation method thereof provided by the present invention may be used to produce a liquid injection composition of piroxicam and hyaluronic acid.
Type:
Application
Filed:
March 7, 2013
Publication date:
February 19, 2015
Applicant:
DONG-A ST CO.,LTD
Inventors:
Soon-Hoe Kim, Mi-Won Son, Sun-Woo Jang, Myung-Joo Kang, Kyung-Wan Ma
Abstract: The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders.
Type:
Application
Filed:
November 24, 2010
Publication date:
June 5, 2014
Applicant:
Dong-A ST Co., Ltd.
Inventors:
Miwon Son, Tae Ho Lee, Sang Zin Choi, Nam Joon Baek, Kang Ro Lee, Ki Hyun Kim, Soon Hoe Kim
Abstract: This invention relates to a pharmaceutical composition and a health functional food for preventing or improving neurodegenerative disorders comprising mixed herb extracts of Dioscorea Rhizoma and Dioscorea nipponica in a weight ratio of 3.5:1 (w/w). The herb extracts mixed Dioscorea Rhizoma and Dioscorea nipponica in a weight ratio of 3.5:1 have the synergetic effects on increasing the amount of nerve growth factor in vivo, increasing the neural cell proliferation, promoting the formation of neuritis and enhancing cognitive abilities. Thus, the herb extracts of the present invention may be used for a pharmaceutical composition and a health functional food for preventing or treating neurodegenerative disorders.
Type:
Application
Filed:
December 29, 2011
Publication date:
February 13, 2014
Applicant:
DONG-A ST CO., LTD.
Inventors:
Soon-Hoe Kim, Mi-Won Son, Sang-Zin Choi, Hye-Ju Kim, Ja-Young Ryu, Sun-Yeou Kim